FCGR2A and neoplasm: Although TIL analyses by flow cytometry were difficult in nivolumab-treated huNOG-FcγR−/− mice, due to the strong tumor rejection or suppression, some of the nivolumab-treated huNOG-FcγR−/− mice had an elevated number of human CD3+ T cells in the tumor compared to control saline-treated huNOG-FcγR−/− mice (Fig. 6).